After the success of Ozempic and Vigovi, pharmaceutical companies have joined the race to develop new weight-loss drugs. This new era of medicine may have more health benefits and fewer harms.
According to the latest report, the development of new GLP-1 drugs has accelerated. Experts say these drugs can go beyond treating diabetes and weight loss to improve liver and heart health and reduce the damage caused by existing drugs, such as muscle wasting.
GLP-1 agonists are commonly used in weight loss medications. These compounds mimic the action of a hormone called GLP-1 by slowing down the digestive process, making people feel fuller for longer.
However, some weight loss medications, including Ozempic, have been criticized for causing muscle loss and nausea.
Researchers will present data on 27 new GLP-1 drugs at the 2024 American Diabetes Association (ADA) conference in Orlando.
Leave feedback about this